Formulation Development Outsourcing Market Size & Growth Forecast 2027–2036, By Segments (Service, End Use, Formulation, Therapeutic Area), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Formulation Development Outsourcing Market size stood at USD 43.3 billion in 2026 and is predicted to grow at a 8.65% CAGR from 2027 to 2036, attaining USD 99.26 billion by 2036. The industry revenue for 2027 is calculated at USD 46.45 billion.
Get more details on this report
Request Free Sample ReportFormulation Development Outsourcing Market Intelligence Snapshot
Regional Market Dynamics
- Asia Pacific holds the largest share due to strong CDMO base, cost-efficient scientific talent, and established pharmaceutical manufacturing and formulation expertise supporting outsourced development demand.
- North America is growing at 8.14% CAGR, driven by rising outsourcing for complex therapeutics, advanced drug delivery programs, and demand for specialized formulation and analytical expertise.
Segment Momentum
- Formulation development held a 74.06% share in 2026 because it directly supports transforming active compounds into stable, scalable drug products ready for manufacturing and clinical development, making it the top outsourcing priority.
- Preformulation is growing the fastest because sponsors increasingly seek early insight into stability, physicochemical properties, and formulation risks to improve development decisions and reduce downstream reformulation efforts.
Market Expansion Drivers
- Expanding biologics and gene therapy pipelines increasing outsourced formulation development demand.
- Rising adoption of AI-enabled formulation design and continuous manufacturing improving scalability efficiency.
- Growing demand for specialized drug delivery technologies accelerating CDMO partnership expansion.
Leading Market Participants
- Major players in the formulation development outsourcing market include Lonza Group AG (Switzerland), Catalent, Inc. (United States), Thermo Fisher Scientific Inc. (United States), Recipharm AB (Sweden), Charles River Laboratories International, Inc. (United States), Eurofins Scientific SE (Luxembourg), SGS SA (Switzerland), Intertek Group plc (United Kingdom), Laboratory Corporation of America Holdings (United States), Element Materials Technology Group Limited (United Kingdom).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 43.3 billion
- 2027 Estimated Market Size: USD 46.45 billion.
- Projected Market Size: USD 99.26 billion by 2036
- Growth Forecast: 8.65% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: Asia Pacific
- High-Growth Regional Hub: North America
- Core Revenue Segment: Formulation Development (Service) | Pharmaceutical and Biopharmaceutical Companies (End Use) | Oral (Formulation) | Infectious Disease (Therapeutic Area)
- Emerging Opportunity Segment: Preformulation (Service) | Government and Academic Institutes (End Use) | Injectable (Formulation) | Cardiovascular (Therapeutic Area)
Market Growth Drivers and Industry Trends
Expanding biologics and gene therapy pipelines increasing outsourced formulation development demand
The expansion of biologics and gene therapy development programs is driving the formulation development outsourcing market as drug developers require specialized expertise to address the complex stability, delivery, and manufacturing requirements of advanced therapies. Biologic molecules and gene-based products can present formulation challenges that differ substantially from conventional small-molecule drugs, increasing the need for external development capabilities, analytical support, and specialized formulation expertise. Outsourcing also allows pharmaceutical developers to access technical resources without building all formulation capabilities internally, particularly during early-stage development and product optimization.
Rising adoption of AI-enabled formulation design and continuous manufacturing improving scalability efficiency
The integration of artificial intelligence into formulation development is enhancing the formulation development outsourcing market by enabling faster evaluation of formulation variables, ingredient interactions, and process conditions. AI-supported approaches can help development teams analyze complex datasets and identify suitable formulations more efficiently, while continuous manufacturing technologies support consistent production and improved process control. The combination of digital formulation design and advanced manufacturing can reduce repetitive development work, improve process scalability, and provide outsourced partners with more efficient approaches to formulation optimization.
Growing demand for specialized drug delivery technologies accelerating CDMO partnership expansion
Increasing demand for advanced drug delivery approaches is strengthening the formulation development outsourcing market as pharmaceutical developers seek specialized capabilities for improving drug stability, bioavailability, controlled release, and targeted delivery. Complex delivery systems often require formulation expertise, specialized equipment, and development knowledge that may not be readily available within conventional pharmaceutical operations. CDMOs can provide these capabilities alongside development and manufacturing support, enabling drug developers to collaborate externally on specialized formulations while addressing technical requirements associated with increasingly complex therapeutic products.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Expanding biologics and gene therapy pipelines increasing outsourced formulation development demand | 2.00% | High | North America, Asia Pacific | High | Near Term |
| Rising adoption of AI-enabled formulation design and continuous manufacturing improving scalability efficiency | 1.70% | Moderate | North America, Europe | Medium | Mid Term |
| Growing demand for specialized drug delivery technologies accelerating CDMO partnership expansion | 1.40% | Moderate | Asia Pacific, Europe | Emerging | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
Asia Pacific (Largest Region)
In the formulation development outsourcing market, Asia Pacific held the largest share in 2026, supported by expanding pharmaceutical manufacturing capabilities, a growing contract development ecosystem, and the increasing complexity of drug formulation requirements. Pharmaceutical companies are increasingly leveraging specialized external partners to access formulation expertise, analytical capabilities, and scalable development infrastructure while improving operational efficiency. The region's cost-competitive research and manufacturing environment, expanding pool of technical talent, and strengthening regulatory capabilities further enhance its attractiveness for outsourced development activities. Growing pharmaceutical production and rising demand for innovative drug delivery systems are also encouraging greater use of external formulation specialists across conventional and advanced therapies.
North America (Fastest-Growing Region)
North America is emerging as the fastest-growing regional market, driven by strong pharmaceutical and biotechnology activity and increasing demand for specialized formulation expertise. The region's mature research infrastructure supports development of complex formulations, including solutions designed to improve drug stability, bioavailability, patient convenience, and therapeutic performance. Increasing pressure to accelerate development programs while managing research costs is encouraging drug developers to collaborate with specialized outsourcing providers. In addition, advances in drug delivery technologies, growing investment in innovative therapies, and access to highly skilled scientific professionals are strengthening the region's outsourcing ecosystem and supporting continued market expansion.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Specialized Development ExpertiseGermany supports formulation development outsourcing through strong technical capabilities in pharmaceutical research and product development. Outsourcing partners are expanding customized formulation services that address increasingly sophisticated therapeutic requirements.
France 🇫🇷
Collaborative Development ServicesFrance continues expanding formulation development outsourcing through partnerships that support complex formulation design and analytical development. External service providers are enhancing integrated capabilities that streamline pharmaceutical product development programs.
Italy 🇮🇹
Flexible Formulation PartnershipsItaly is strengthening formulation development outsourcing by supporting pharmaceutical companies with specialized formulation expertise and scalable development resources. Outsourcing providers are focusing on efficient project execution and tailored technical services across multiple dosage forms.
Japan 🇯🇵
Advanced Formulation CollaborationJapan emphasizes formulation development outsourcing for innovative drug products requiring specialized scientific expertise and rigorous quality standards. Companies increasingly engage external development partners to complement internal research capabilities and improve project flexibility.
South Korea 🇰🇷
Outsourcing Innovation HubSouth Korea is strengthening formulation development outsourcing by expanding contract development capabilities and advanced laboratory infrastructure. Pharmaceutical companies are seeking external partners that provide flexible development services for diverse therapeutic pipelines.
United States 🇺🇸
Complex Pipeline SupportThe U.S. formulation development outsourcing market is driven by demand for specialized expertise across biologics, novel drug delivery, and early-stage development. Pharmaceutical companies increasingly collaborate with outsourcing partners to accelerate formulation optimization and development efficiency.
Segment Leadership and Growth Trends
Formulation Development Outsourcing Market Share (%), by Service, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportService Segment Analysis: Formulation Development (Largest Segment) vs Preformulation (Fastest-Growing Segment)
Formulation development accounted for the largest share of the formulation development outsourcing market in 2026, with a 74.06% share. Its strong position reflects the complexity of converting active pharmaceutical ingredients into stable, effective, and patient-appropriate dosage forms while meeting performance and quality requirements. Outsourcing formulation development enables pharmaceutical and biopharmaceutical companies to access specialized expertise, laboratory capabilities, and formulation technologies without building all required resources internally. The increasing complexity of drug candidates is further encouraging organizations to use external partners to accelerate formulation optimization and reduce development challenges.
Preformulation is the fastest-growing service segment, supported by greater emphasis on identifying critical material and drug characteristics before extensive formulation work begins. Preformulation studies help evaluate properties such as stability, solubility, compatibility, and behavior of active ingredients, providing an important foundation for selecting suitable formulation strategies. Greater focus on reducing development risks and improving downstream formulation efficiency is encouraging sponsors to engage specialized providers earlier in the drug development process.
End Use Segment Analysis: Pharmaceutical and Biopharmaceutical Companies (Largest Segment) vs Government and Academic Institutes (Fastest-Growing Segment)
The pharmaceutical and biopharmaceutical companies segment dominated the formulation development outsourcing market in 2026, holding a 74.06% share. These organizations frequently outsource formulation activities to access specialized scientific capabilities, advanced development infrastructure, and flexible resources while concentrating internal teams on core research and commercialization priorities. The growing complexity of drug pipelines and the need to efficiently translate promising candidates into viable dosage forms are reinforcing the role of external formulation development partners.
Government and academic institutes represent the fastest-growing end-use segment as research institutions increasingly pursue translational development and require specialized formulation capabilities to move discoveries toward practical therapeutic applications. Outsourcing provides access to technical expertise and development infrastructure that may not be readily available within academic or public research settings. Greater collaboration between research organizations and specialized formulation providers is consequently supporting the expansion of outsourced formulation activities in this segment.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Service | Preformulation, Formulation Development | Formulation Development | Preformulation |
| End Use | Pharmaceutical and Biopharmaceutical Companies, Government and Academic Institutes, Others | Pharmaceutical and Biopharmaceutical Companies | Government and Academic Institutes |
| Formulation | Oral, Injectable, Topical, Others | Oral | Injectable |
| Therapeutic Area | Infectious Disease, Neurology, Hematology, Respiratory, Cardiovascular, Dermatology, Others | Infectious Disease | Cardiovascular |
Competitive Landscape and Market Positioning
Prominent players in the formulation development outsourcing market:
1. Lonza Group AG (Switzerland)
2. Catalent Inc. (United States)
3. Thermo Fisher Scientific Inc. (United States)
4. Recipharm AB (Sweden)
5. Charles River Laboratories International Inc. (United States)
6. Eurofins Scientific SE (Luxembourg)
7. SGS SA (Switzerland)
8. Intertek Group plc (United Kingdom)
9. Laboratory Corporation of America Holdings (United States)
10. Element Materials Technology Group Limited (United Kingdom)
The formulation development outsourcing market is evolving through specialized pharmaceutical development services. Innovation is improving formulation efficiency and product customization. Collaborative research efforts are strengthening outsourcing capabilities. Continuous advancement is supporting faster drug development cycles.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Lonza Group AG (Switzerland) | |||||||
| Catalent Inc. (United States) | |||||||
| Thermo Fisher Scientific Inc. (United States) | |||||||
| Recipharm AB (Sweden) | |||||||
| Charles River Laboratories International Inc. (United States) | |||||||
| Eurofins Scientific SE (Luxembourg) | |||||||
| SGS SA (Switzerland) | |||||||
| Intertek Group plc (United Kingdom) | |||||||
| Laboratory Corporation of America Holdings (United States) | |||||||
| Element Materials Technology Group Limited (United Kingdom). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Catalent, Inc. | 2025 | Catalent, Inc. introduced new advanced biologics formulation technologies to its portfolio, aimed at accelerating the development and delivery of complex life-changing therapies. These platforms are designed to optimize drug performance and stability for diverse modalities, supporting faster transitions from early-stage design to commercial-scale manufacturing. |
| Recipharm AB | 2025 | Recipharm AB made strategic investments in continuous manufacturing systems specifically for oral formulation development. These systems are intended to improve production efficiency, enhance process control, and support the accelerated development and scale-up of solid oral dosage forms. |
| CoreRx Inc. | Apr-24 | CoreRx Inc. acquired Societal CDMO, Inc. in a deal valued at approximately USD 130 million. The acquisition integrates Societal CDMO’s expertise in complex small-molecule formulation with CoreRx’s existing capabilities, creating an expanded CDMO platform that provides end-to-end services from early-stage development through commercial-scale manufacturing and packaging. |
| Lonza | 2024 | Lonza significantly expanded its sterile injectable manufacturing capabilities, supported by a CHF 500 million investment. The expansion includes new technology-enabled solutions and increased capacity across its global network, specifically designed to mitigate complexity in drug product development and meet growing commercial demands for various biologics and modalities. |
| Charles River Laboratories | 2024 | Charles River Laboratories launched enhanced oncology formulation support services as part of its "One Step" manufacturing suite. The services integrate specialized drug discovery chemistry with formulation development, allowing for optimized compound design and more predictable outcomes for oncology programs from discovery through IND-enabling studies. |
| Thermo Fisher Scientific | 2023 | Thermo Fisher Scientific expanded its pharmaceutical analytical testing infrastructure, bolstering its ability to support clients in solving complex analytical challenges. This expansion enhances the company's capability to provide critical data for the development and manufacturing of safe, high-quality therapies through its integrated service brands, including Patheon and PPD. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Formulation Development Outsourcing Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Drug Development Phase | Preclinical Development, Phase I, Phase II, Phase III, Commercial & Lifecycle Management |
| Molecule Type | Small Molecules, Biologics, Peptides & Oligonucleotides, Other Advanced Modalities |
| Outsourcing Model | Full-Service Outsourcing, Functional Service Outsourcing, Project-Based Outsourcing |
Formulation Development Outsourcing Market — Custom
| Custom Chapter | Custom Details |
|---|---|
| Outsourcing Partner Selection & Benchmarking |
|
| Pharmaceutical Outsourcing Location Competitiveness Assessment |
|
| Clinical-to-Commercial Technology Transfer Strategies |
|
Need a different cut of the data?
Request Custom ResearchWhat is the market size of formulation development outsourcing?
How will the formulation development outsourcing industry grow in terms of size and CAGR by 2036?
How are complex drug pipelines changing outsourcing strategies in the formulation development market?
Why are technology-enabled capabilities becoming important in formulation development outsourcing partnerships?
Why is formulation development the largest service segment in the formulation development outsourcing market?
Why is preformulation the fastest-growing service segment in the formulation development outsourcing market?
Why does Asia Pacific lead the formulation development outsourcing market?
What is driving growth in North America?
Which organizations are considered leaders in the formulation development outsourcing landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Why It Matters | Reference |
|---|---|---|
| World Health Organization (WHO) | Global health statistics, disease burden, healthcare policies | www.who.int |
| U.S. Food & Drug Administration (FDA) | Medical devices, pharmaceuticals, diagnostics, approvals | www.fda.gov |
| European Medicines Agency (EMA) | Pharmaceutical approvals and regulatory guidance in Europe | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | Disease surveillance, public health, epidemiology | www.cdc.gov |
| National Institutes of Health (NIH) | Biomedical research, clinical studies, funding | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | Biomedical databases, PubMed, genomics | www.ncbi.nlm.nih.gov |
| PubMed | Peer-reviewed biomedical literature | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | Global clinical trial registry | clinicaltrials.gov |
| International Organization for Standardization (ISO) | Medical device quality and healthcare standards | www.iso.org |
| ASTM International | Medical device testing and material standards | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | Medical devices and diagnostics industry | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | Medical device innovation and regulatory science | mdic.org |
| Biotechnology Innovation Organization (BIO) | Biotechnology industry developments | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | Global pharmaceutical industry | www.ifpma.org |
| U.S. Pharmacopeia (USP) | Drug quality standards and reference materials | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | European pharmaceutical quality standards | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | Veterinary healthcare and animal diseases | www.woah.org |
| American Hospital Association (AHA) | Hospital operations and healthcare delivery | www.aha.org |
| OECD Health | International healthcare expenditure and system statistics | www.oecd.org/health |
| World Bank Data | Healthcare expenditure and demographic indicators | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization